From Dr. Bruce Cheson’s electric speech on how it all started with pentostatin in hairy cell leukemia, to the introduction of bendamustine in indolent lymphoma, to the development of R-squared (an inn...
"The panel urges clinicians to consider the pretest probability of AD pathology for each patient when deciding whether or not to use a BBM test,” and not as a standalone diagnostic tool.
Neuroimaging detects reduced grey matter in multiple brain regions among breast cancer patients after chemotherapy, raising concern for long-term cognitive risks.
Researchers visualize how insulin travels from the nose to the brain using PET scans, uncovering differences in uptake based on cognition, blood pressure, and sex.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
An investigational Fas inhibitor demonstrated encouraging results in patients with geographic atrophy (GA) in a phase 1b clinical trial. In the study, eyes treated with ONL1204 (ONL Therapeutics) showed reductions in GA lesion growth at 6 months of up to 50% compared to sham-treated eyes after 2 injections spaced 3 months apart, and a 42% reduction in lesion growth compared to fellow untreated eyes after a single injection.
The combination of adagrasib and cetuximab may show clinical activity and promising survival outcomes in patients with metastatic, heavily pretreated, KRAS G12C–mutated colorectal cancer.